Applicant, as named in the Orange Book

Alcon Labs Inc

Alcon Inc · NYSE: ALC

Company and ticker: cliffwatch mapping, checked against SEC EDGAR · SEC filings

Next listed expiry: Simbrinza on 30 Oct 2030. 7 products with live protection, 4 without.

Products with listed protection

Drug	Ingredient	Earliest generic entry	Basis
Simbrinza NDA 204251 brimonidine tartrate; brinzolamide	brimonidine tartrate; brinzolamide	30 Oct 2030 patent	patent
Pataday Once Daily Relief NDA 206276 olopatadine hydrochloride	olopatadine hydrochloride	19 May 2032 patent	patent
Eysuvis NDA 210933 loteprednol etabonate	loteprednol etabonate	3 May 2033 patent	patent
Inveltys NDA 210565 loteprednol etabonate	loteprednol etabonate	3 May 2033 patent	patent
Rhopressa NDA 208254 netarsudil mesylate	netarsudil mesylate	14 Mar 2034 patent	patent
Rocklatan NDA 208259 latanoprost; netarsudil dimesylate	latanoprost; netarsudil dimesylate	14 Mar 2034 patent	patent
Tryptyr NDA 217370 acoltremon	acoltremon	16 Dec 2042 patent	patent

Isopto Atropine · Generic approved · ANDA 219628, Sentiss PharmaApproved 16 Oct 2026Detected 26 Oct 2026
Pataday Once Daily Relief · Generic approved · ANDA 213514, GlandApproved 6 Jan 2026Detected 25 Oct 2026

Products without listed protection (4)

Drug	Ingredient	Earliest generic entry	Basis
Fluorescite NDA 021980 fluorescein sodium	fluorescein sodium	open now no listed protection	no listed protection
Isopto Atropine NDA 208151 atropine sulfate	atropine sulfate	open now no listed protection	no listed protection
Pataday Once Daily Relief NDA 021545 olopatadine hydrochloride	olopatadine hydrochloride	open now no listed protection	no listed protection
Pataday Twice Daily Relief NDA 020688 olopatadine hydrochloride	olopatadine hydrochloride	open now no listed protection	no listed protection